We have previously shown that SOX2 is a marker of poor patient prognosis in GC, which would be in accordance with the more aggressive behavior of the cells that express SOX2, namely increased proliferation, increased tumor-formation, and increased drug resistance, observed in this study [38]. This evidence concerns the gene SOX2 and gastric cancer.